**Edesa Biotech Amends Financing Agreement with Government of Canada** Edesa Biotech Inc. has announced an amendment to its multi-year funding agreement with the Government of Canada, originally established to support the development of its experimental drug EB05 for Acute Respiratory Distress Syndrome $(ARDS)$. Under the revised terms, the project completion date has been extended to December 31, 2028, with the agreement's expiration now set for the later of December 31, 2045, or the date of final repayment. The amendment also updates the project's scope to focus on general ARDS, reflecting a shift from the initial emphasis on Covid-19-induced ARDS, and aligns with a fully funded U.S. government study involving EB05. Additionally, the repayment schedule has been modified: annual payments will not begin until 2032, and only if Edesa Biotech generates gross revenue. The agreement provides up to CAD $23 million ($17 million USD) in partially repayable funding.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-006188), on September 30, 2025, and is solely responsible for the information contained therein.
Comments